Protagonist Therapeutics, Inc — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Standard Sarbanes-Oxley certifications signed by CEO Dinesh V. Patel and CFO Asif Ali on August 5, 2026 for the Q2 2026 10-Q period ended June 30, 2026. Executives certify financial statements fairly present the company's condition, that disclosure controls are effective, and no material weaknesses in internal controls or fraud involving management were identified.
Why this rating
Routine regulatory certification; boilerplate SOX compliance with no substantive business or financial disclosures.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.